The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q3 2011. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars.
| Rank |
Drug |
Sales ($000) |
|
|
| 1 |
Lipitor
Pfizer Inc |
1,969,877 |
1.05% |
Stats |
| 2 |
Plavix
Bristol-Myers Squibb Company |
1,630,951 |
-3.97% |
Stats |
| 3 |
Nexium
AstraZeneca Pharmaceuticals |
1,441,825 |
-5.64% |
Stats |
| 4 |
Abilify
Otsuka Pharmaceutical Co. |
1,249,763 |
-1.34% |
Stats |
| 5 |
Singulair
Merck & Co., Inc. |
1,110,538 |
-4.34% |
Stats |
6 ( 1) |
Seroquel
AstraZeneca Pharmaceuticals |
1,105,210 |
-2.15% |
Stats |
7 ( 1) |
Advair Diskus
GlaxoSmithKline |
1,061,099 |
-7.01% |
Stats |
| 8 |
Crestor
AstraZeneca Pharmaceuticals |
1,053,383 |
-1.78% |
Stats |
| 9 (3) |
Cymbalta
Eli Lilly and Company |
913,796 |
6.08% |
Stats |
| 10 |
Remicade
Centocor Ortho Biotech, Inc |
879,054 |
1.52% |
Stats |
| 11 (3) |
Humira
Abbott Laboratories |
877,641 |
3.95% |
Stats |
| 12 (1) |
Enbrel
Amgen Inc. |
858,997 |
1.27% |
Stats |
| 13 (2) |
Zyprexa
Eli Lilly and Company |
828,973 |
-4.04% |
Stats |
| 14 (1) |
Neulasta
Amgen Inc. |
786,464 |
-3.86% |
Stats |
| 15 (6) |
Actos
Takeda Pharmaceuticals North America, Inc |
779,504 |
-11.05% |
Stats |
| 16 |
Rituxan
Genentech, Inc |
721,408 |
-1.77% |
Stats |
| 17 (2) |
Copaxone
Teva Pharmaceuticals |
708,803 |
-1.66% |
Stats |
| 18 |
Lexapro
Forest Pharmaceuticals, Inc |
696,883 |
-3.33% |
Stats |
| 19 (2) |
OxyContin
|
687,676 |
-5.33% |
Stats |
| 20 (2) |
Atripla
Gilead Sciences, Inc. |
627,084 |
0.42% |
Stats |
| 21 |
Avastin
Genentech, Inc |
626,618 |
-3.57% |
Stats |
| 22 (2) |
Epogen
Amgen Inc. |
619,828 |
-13.96% |
Stats |
| 23 |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc |
570,706 |
-1.46% |
Stats |
| 24 |
Januvia
Merck & Co., Inc. |
515,840 |
1.19% |
Stats |
| 25 (2) |
Truvada
Gilead Sciences, Inc. |
487,444 |
1.15% |
Stats |
| 26 |
Lantus
Sanofi-Aventis |
470,948 |
-3.61% |
Stats |
| 27 (2) |
Diovan
Novartis Corporation |
450,115 |
-9.44% |
Stats |
| 28 (2) |
Lucentis
Genentech, Inc |
429,393 |
1.13% |
Stats |
| 29 |
Lyrica
Pfizer Inc |
426,822 |
-2.94% |
Stats |
| 30 (2) |
Celebrex
Pfizer Inc |
421,670 |
-4.82% |
Stats |
| 31 (1) |
Herceptin
Genentech, Inc |
395,804 |
-0.64% |
Stats |
| 32 (1) |
Diovan HCT
Novartis Corporation |
387,064 |
-8.54% |
Stats |
| 33 |
Avonex
Biogen Idec |
379,457 |
-0.05% |
Stats |
| 34 (2) |
Lantus Solostar
Sanofi-Aventis |
376,208 |
4.53% |
Stats |
| 35 (2) |
Gleevec
Novartis Corporation |
374,171 |
5.88% |
Stats |
| 36 (2) |
Namenda
Forest Pharmaceuticals, Inc |
359,537 |
-2.67% |
Stats |
| 37 (2) |
One Touch Ultra
|
359,152 |
-2.46% |
Stats |
| 38 (1) |
enoxaparin
Generic |
354,293 |
5.21% |
Stats |
| 39 (16) |
Eloxatin
Sanofi-Aventis |
353,940 |
34.41% |
Stats |
40 ( ) |
Incivek
Vertex Pharmaceuticals |
335,582 |
 |
Stats |
| 41 (2) |
Geodon
Pfizer Inc |
334,275 |
3.81% |
Stats |
| 42 |
TriCor
Abbott Laboratories |
321,079 |
-0.32% |
Stats |
| 43 (4) |
Suboxone
Reckitt Benckiser Pharmaceuticals Inc. |
311,941 |
6.42% |
Stats |
| 44 (4) |
Zetia
Merck & Co., Inc. |
311,388 |
-7.20% |
Stats |
| 45 (1) |
Vyvanse
Shire US Inc |
308,386 |
1.08% |
Stats |
| 46 |
Lidoderm
Endo Pharmaceuticals |
288,696 |
-2.41% |
Stats |
| 47 (3) |
Provigil
Cephalon, Inc. |
285,873 |
3.92% |
Stats |
| 48 (29) |
Varivax
Merck & Co., Inc. |
276,857 |
42.23% |
Stats |
| 49 (4) |
Niaspan
Abbott Laboratories |
267,018 |
-11.86% |
Stats |
| 50 (1) |
AndroGel
Abbott Laboratories |
265,966 |
-5.89% |
Stats |
| 51 (3) |
Aranesp
Amgen Inc. |
261,967 |
-10.25% |
Stats |
| 52 (31) |
methylphenidate
Generic |
260,992 |
41.59% |
Stats |
| 53 (12) |
Procrit
Janssen Pharmaceuticals, Inc |
260,610 |
-21.61% |
Stats |
| 54 (5) |
Rebif
|
257,535 |
1.48% |
Stats |
| 55 (10) |
Seroquel XR
AstraZeneca Pharmaceuticals |
256,141 |
2.65% |
Stats |
| 56 (1) |
Combivent
Boehringer Ingelheim Pharmaceuticals, Inc |
255,615 |
-0.53% |
Stats |
| 57 (9) |
amphetamine/dextroamphetamine
Generic |
255,231 |
3.47% |
Stats |
| 58 (5) |
Alimta
Eli Lilly and Company |
255,178 |
1.37% |
Stats |
| 59 (5) |
Viagra
Pfizer Inc |
253,141 |
1.29% |
Stats |
| 60 (1) |
Novolog
Novo Nordisk Inc. |
249,591 |
-0.96% |
Stats |
| 61 (7) |
Vytorin
Merck & Co., Inc. |
244,078 |
-8.10% |
Stats |
| 62 (9) |
Lovenox
Sanofi-Aventis |
243,627 |
-8.33% |
Stats |
| 63 (4) |
Humalog
Eli Lilly and Company |
242,208 |
-0.75% |
Stats |
| 64 (4) |
Symbicort
AstraZeneca Pharmaceuticals |
240,761 |
-4.65% |
Stats |
| 65 (5) |
Neupogen
Amgen Inc. |
237,915 |
0.69% |
Stats |
| 66 (8) |
ProAir HFA
Teva Pharmaceuticals |
236,487 |
9.84% |
Stats |
| 67 (9) |
Lovaza
GlaxoSmithKline |
231,896 |
-8.96% |
Stats |
| 68 (17) |
Nasonex
Merck & Co., Inc. |
230,174 |
-14.77% |
Stats |
| 69 (1) |
metoprolol
Generic |
229,868 |
-4.57% |
Stats |
| 70 (1) |
Reyataz
Bristol-Myers Squibb Company |
226,939 |
-2.22% |
Stats |
| 71 (9) |
Adderall XR
Shire US Inc |
219,669 |
-12.77% |
Stats |
| 72 (3) |
Flovent HFA
GlaxoSmithKline |
213,037 |
-10.26% |
Stats |
| 73 (17) |
Solodyn
Medicis Pharmaceutical Corporation |
211,536 |
18.36% |
Stats |
| 74 (1) |
fentanyl
Generic |
210,250 |
-2.89% |
Stats |
| 75 (3) |
Aciphex
Eisai Corporation |
209,632 |
-6.32% |
Stats |
| 76 (1) |
Levemir
Novo Nordisk Inc. |
201,824 |
1.83% |
Stats |
| 77 () |
Prevnar 13
Wyeth |
194,677 |
|
Stats |
| 78 (6) |
Isentress
Merck & Co., Inc. |
194,642 |
6.05% |
Stats |
| 79 (1) |
Cialis
Eli Lilly and Company |
192,331 |
1.03% |
Stats |
| 80 (6) |
NovoLog FlexPen
Novo Nordisk Inc. |
189,267 |
4.15% |
Stats |
| 81 (5) |
Lunesta
Sunovion Pharmaceuticals Inc. |
188,531 |
-3.44% |
Stats |
| 82 (4) |
Janumet
Merck & Co., Inc. |
188,050 |
-2.60% |
Stats |
| 83 (1) |
docetaxel
Generic |
179,876 |
-2.92% |
Stats |
| 84 (3) |
Evista
Eli Lilly and Company |
176,642 |
-2.26% |
Stats |
| 85 (10) |
budesonide
Generic |
175,543 |
5.36% |
Stats |
| 86 (2) |
Restasis
Allergan, Inc |
175,330 |
-2.15% |
Stats |
| 87 (2) |
Betaseron
Bayer Healthcare Pharmaceuticals |
173,769 |
-2.89% |
Stats |
| 88 (3) |
Zyvox
Pfizer Inc |
170,871 |
-3.78% |
Stats |
| 89 (5) |
Velcade
Takeda Pharmaceuticals North America, Inc |
170,665 |
2.42% |
Stats |
| 90 (3) |
Erbitux
Bristol-Myers Squibb Company |
167,909 |
-2.48% |
Stats |
| 91 () |
Xeloda
Roche Pharmaceuticals |
165,875 |
|
Stats |
| 92 () |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc |
164,496 |
|
Stats |
| 93 (1) |
Benicar
Daiichi Sankyo |
161,995 |
-5.94% |
Stats |
| 94 () |
Opana ER
Endo Pharmaceuticals |
161,602 |
|
Stats |
| 95 (4) |
Synthroid
Abbott Laboratories |
160,078 |
-0.04% |
Stats |
| 96 (2) |
acetaminophen/hydrocodone
Generic |
159,532 |
-0.90% |
Stats |
| 97 (1) |
Zometa
|
159,059 |
-4.27% |
Stats |
| 98 () |
Fluvirin
|
158,294 |
|
Stats |
| 99 (2) |
VESIcare
Astellas Pharma US |
157,269 |
-2.74% |
Stats |
| 100 () |
Prezista
Janssen Pharmaceuticals, Inc |
155,442 |
|
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
1)
1)
)
